From the MTA-SE Momentum Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Bioinformatics Research Group, Bioinformatics and Sequencing Core Facilities, Szentaágothai Research Centre, University of Peés, Peés, Hungary; Department of Clinical Molecular Biology, Medical University of Bialystok, Białystok, Poland; Medical University of Bialystok, Białystok, Poland.
J Neuropathol Exp Neurol. 2020 Feb 1;79(2):176-183. doi: 10.1093/jnen/nlz125.
Primary central nervous system lymphomas (PCNSL) are aggressive non-Hodgkin lymphomas affecting the central nervous system (CNS). Although immunophenotyping studies suggested an uniform activated B-cell (ABC) origin, more recently a spectrum of ABC and germinal center B-cell (GC) cases has been proposed, with the molecular subtypes of PCNSL still being a matter of debate. With the emergence of novel therapies demonstrating different efficacy between the ABC and GC patient groups, precise assignment of molecular subtype is becoming indispensable. To determine the molecular subtype of 77 PCNSL and 17 secondary CNS lymphoma patients, we used the NanoString Lymphoma Subtyping Test (LST), a gene expression-based assay representing a more accurate technique of subtyping compared with standard immunohistochemical (IHC) algorithms. Mutational landscapes of 14 target genes were determined using ultra-deep next-generation sequencing. Using the LST-assay, a significantly lower proportion (80% vs 95%) of PCNSL cases displayed ABC phenotype compared with the IHC-based characterization. The most frequently mutated genes included MYD88, PIM1, and KMT2D. In summary, we successfully applied the LST-assay for molecular classification of PCNSL, reporting higher proportion of cases with GC phenotype compared with IHC analyses, leading to a more precise patient stratification potentially applicable in the diagnostic algorithm of PCNSL.
原发性中枢神经系统淋巴瘤(PCNSL)是一种侵袭性的非霍奇金淋巴瘤,影响中枢神经系统(CNS)。尽管免疫表型研究表明其具有一致的激活 B 细胞(ABC)起源,但最近提出了一系列 ABC 和生发中心 B 细胞(GC)病例,PCNSL 的分子亚型仍存在争议。随着新型治疗方法的出现,ABC 和 GC 患者群体之间的疗效存在差异,因此精确分配分子亚型变得不可或缺。为了确定 77 例 PCNSL 和 17 例继发性中枢神经系统淋巴瘤患者的分子亚型,我们使用了基于基因表达的 NanoString 淋巴瘤亚型测试(LST),与标准免疫组织化学(IHC)算法相比,这是一种更准确的亚型技术。使用超深度下一代测序确定了 14 个靶基因的突变景观。使用 LST 检测,与基于 IHC 的特征相比,PCNSL 病例中 ABC 表型的比例明显较低(80%比 95%)。最常突变的基因包括 MYD88、PIM1 和 KMT2D。总之,我们成功地应用 LST 检测进行 PCNSL 的分子分类,报告了与 IHC 分析相比,GC 表型的病例比例更高,从而实现了更精确的患者分层,可能适用于 PCNSL 的诊断算法。